Home › Funds › ORBIMED ADVISORS LLC › URGN
ORBIMED ADVISORS LLC position in URGN
UROGEN PHARMA LTD · Health Care
ORBIMED ADVISORS LLC reported holding 988,487 shares of URGN (UROGEN PHARMA LTD) in its Q3 2026 13F filing — a position valued at US$40.2M, representing 0.82% of its reported portfolio and ranking #30 among its reported holdings. ORBIMED ADVISORS LLC has disclosed URGN holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's URGN position evolved
ORBIMED ADVISORS LLC first disclosed a stake in URGN in Q2 2025 at 478,400 shares (US$6.6M). The position peaked in Q3 2026 at 988,487 shares, worth US$40.2M. Across 6 filings, ORBIMED ADVISORS LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 988,487 shares valued at US$40.2M — an increase of 312,300 shares quarter over quarter.. Notable position changes include a 44% increase in Q3 2025 (shares rose 17% over the following quarter), a 27% increase in Q4 2025 (shares fell 23% over the following quarter), a 46% increase in Q3 2026 (shares fell 31% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 478.40K | $6.55M | New |
| Q3 2025 | 689.00K | $13.75M | Add |
| Q4 2025 | 875.49K | $20.50M | Add |
| Q1 2026 | 875.49K | $15.74M | Hold |
| Q2 2026 | 676.19K | $24.88M | Reduce |
| Q3 2026 | 988.49K | $40.16M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About URGN and 13F data
URGN (UROGEN PHARMA LTD) is a Health Care company. 48 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$184.6M), Kynam Capital Management, LP (US$98.9M), Jefferies Financial Group Inc. (US$89.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding URGN
- RTW INVESTMENTS, LP 4.54M sh · $184.62M · Q3 2026
- Kynam Capital Management, LP 2.43M sh · $98.90M · Q3 2026
- Jefferies Financial Group Inc. 2.20M sh · $89.37M · Q3 2026
- ACORN CAPITAL ADVISORS, LLC 1.65M sh · $66.98M · Q3 2026
- Opaleye Management Inc. 1.44M sh · $52.99M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.15M sh · $46.67M · Q3 2026
- MPM BioImpact LLC 909.69K sh · $36.96M · Q3 2026
- Parkman Healthcare Partners LLC 750.20K sh · $30.48M · Q3 2026
- Boxer Capital Management, LLC 500.00K sh · $20.32M · Q3 2026
- Elmind Capital, LP 491.10K sh · $19.95M · Q3 2026
- ADAR1 Capital Management, LLC 369.79K sh · $15.02M · Q3 2026
- NEXT CENTURY GROWTH INVESTORS LLC 297.08K sh · $12.07M · Q3 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held URGN?
ORBIMED ADVISORS LLC has disclosed URGN holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is ORBIMED ADVISORS LLC's current position in URGN?
As of Q3 2026, ORBIMED ADVISORS LLC holds 988.49K shares of URGN (UROGEN PHARMA LTD), valued at $40.16M, representing 0.82% of its reported portfolio and ranking #30.
Has ORBIMED ADVISORS LLC been buying or selling URGN?
In the latest 13F filing (Q3 2026), ORBIMED ADVISORS LLC increased its position in URGN. The position peaked in Q3 2026 at 988.49K shares.
Which other funds hold URGN?
Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.